Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yoshitaka Isaka M.D., Ph.D."'
Autor:
Hidetoshi Tsuda, Kenichi Yamahara, Kentaro Otani, Masayoshi Okumi, Koji Yazawa, Jun-Ya Kaimori, Akihiko Taguchi, Kenji Kangawa, Tomoaki Ikeda, Shiro Takahara, Yoshitaka Isaka M.D., Ph.D.
Publikováno v:
Cell Transplantation, Vol 23 (2014)
Mesenchymal stem cells (MSCs) are an attractive therapeutic cell source for treating renal diseases. MSC administration has been shown to improve renal function, although the underlying mechanisms are not completely understood. We recently showed tha
Externí odkaz:
https://doaj.org/article/ca13213768e04039beafe2265526e0cc
Autor:
Toyofumi Abe, Yoshitaka Isaka M.D., Ph.D., Ryoichi Imamura, Yoichi Kakuta, Masayoshi Okumi, Koji Yazawa, Naotsugu Ichimaru, Hidetoshi Tsuda, Norio Nonomura, Shiro Takahara, Akihiko Okuyama
Publikováno v:
Cell Transplantation, Vol 21 (2012)
The introduction of cyclosporine (CsA) has improved graft survival, but it causes nephropathy, which limits its clinical utility. Recently, we reported that carbamylated erythropoietin (CEPO) protected kidneys from ischemia reperfusion injury as well
Externí odkaz:
https://doaj.org/article/9dfbecdcdfaa4ee6be8ed8195e0b35c5
Autor:
Ryoichi Imamura, Yoshitaka Isaka M.D., Ph.D., Ruben M. Sandoval, Asaf Ori, Swetlana Adamsky, Elena Feinstein, Bruce A. Molitoris, Shiro Takahara
Publikováno v:
Cell Transplantation, Vol 19 (2010)
Renal ischemia-reperfusion (I/R) injury, which is unavoidable in renal transplantation, frequently influences both short- and long-term allograft survival. Despite decades of laboratory and clinical investigations, and the advent of renal replacement
Externí odkaz:
https://doaj.org/article/37ca0af9ecc44f09bb083fbc76f0b7fd
Autor:
Ryoichi Imamura, Masayoshi Okumi, Yoshitaka Isaka M.D., Ph.D., Naotsugu Ichimaru, Toshiki Moriyama, Enyu Imai, Norio Nonomura, Shiro Takahara, Akihiko Okuyama
Publikováno v:
Cell Transplantation, Vol 17 (2008)
Several studies have shown that erythropoietin (EPO) can protect the kidneys from ischemia-reperfusion injury and can raise the hemoglobin (Hb) concentration. Recently, the EPO molecule modified by carbamylation (CEPO) has been identified and was dem
Externí odkaz:
https://doaj.org/article/32d6a3a03ab94be6847cac07b942c806